Savara Inc Debt Instrument, Fee Amount
Savara Inc (SVRA) had Debt Instrument, Fee Amount of $418.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Notes › Debt › Debt Instruments
us-gaap:DebtInstrumentFeeAmount · last filed 2026-08-11
- 2026-06-30: Debt Instrument, Fee Amount $418.00K.
- 2026-03-31: Debt Instrument, Fee Amount $356.00K.
- 2025-12-31: Debt Instrument, Fee Amount $411.00K.
- 2025-09-30: Debt Instrument, Fee Amount $433.00K.
| Period end | Debt Instrument, Fee Amount |
|---|---|
| 2026-06-30 | $418.00K 10-Q · filed 2026-08-11 |
| 2026-03-31 | $356.00K 10-Q · filed 2026-05-12 |
| 2025-12-31 | $411.00K 10-K · filed 2026-03-13 |
| 2025-09-30 | $433.00K 10-Q · filed 2025-11-12 |
| 2025-06-30 | $457.00K 10-Q · filed 2025-08-13 |
| 2025-03-31 | $481.00K 10-Q · filed 2025-05-13 |
| 2024-12-31 | $253.00K 10-Q · filed 2025-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |